SRD5A3
Appearance
| SRD5A3 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | SRD5A3, CDG1P, CDG1Q, KRIZI, SRD5A2L, SRD5A2L1, steroid 5 alpha-reductase 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 611715; MGI: 1930252; HomoloGene: 41385; GeneCards: SRD5A3; OMA:SRD5A3 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Steroid 5-alpha-reductase 3, also known as 3-oxo-5-alpha-steroid 4-dehydrogenase 3, is an enzyme that in humans is encoded by the SRD5A3 gene.[5][6] It is one of three forms of 5α-reductase. Unlike SRD5A1 and SRD5A2, SRD5A3 has no apparent form in androgen processing or signaling. Instead, SRD5A3 reduces polyprenol to dolichol, which is necessary for N-linked glycosylation of proteins and some lipids.[7]
See also
[edit]- SRD5A3-CDG
- Congenital disorder of glycosylation
- Kahrizi syndrome, a syndrome caused by a mutation in this gene
References
[edit]- 1 2 3 GRCh38: Ensembl release 89: ENSG00000128039 – Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000029233 – Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Entrez Gene: steroid 5 alpha-reductase 3".
- ↑ Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, et al. (January 2008). "Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer". Cancer Science. 99 (1): 81–86. doi:10.1111/j.1349-7006.2007.00656.x. PMC 11158902. PMID 17986282. S2CID 51733620.
- ↑ Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, et al. (July 2010). "SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder". Cell. 142 (2): 203–217. doi:10.1016/j.cell.2010.06.001. PMC 2940322. PMID 20637498.
Further reading
[edit]- Payne AH, Hales DB (Dec 2004). "Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones". Endocrine Reviews. 25 (6): 947–970. doi:10.1210/er.2003-0030. PMID 15583024.
- Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, et al. (Jul 2010). "SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder". Cell. 142 (2): 203–217. doi:10.1016/j.cell.2010.06.001. PMC 2940322. PMID 20637498.